SCHEMBL3986152

SCHEMBL3986152

CC(=O)Nc1cc(Oc2cccc(CCNC(=O)c3cccc(Br)c3)c2)ccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 6/20 0.56
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
LMNA P02545 1/20 0.49
HPGD P15428 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.46
BRAF P15056 1/20 0.45
KDM5B Q9UGL1 2/20 0.45
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
HRH3 Q9Y5N1 1/20 0.44
NR3C2 P08235 1/20 0.43
LOX P28300 2/20 0.43
LOXL2 Q9Y4K0 2/20 0.43
KDM4E B2RXH2 1/20 0.43
KDM5A P29375 1/20 0.43
KDM5C P41229 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119964 0.90 NPC1 (0.55) GRM5NPC1RAB9ALMNABRAF
SCHEMBL3991944 0.89 GRM5 (0.58) GRM5NPC1RAB9ALMNAL3MBTL1
SCHEMBL4115551 0.87 BRAF (0.50) GRM5NPC1RAB9ABRAFKDM5B
SCHEMBL3984127 0.86 GPR52 (0.52) GRM5BRAFHRH3NR3C2
SCHEMBL4293095 0.86 GRM5 (0.49) GRM5NPC1RAB9ABRAFCA1
SCHEMBL14273330 0.84 NPC1 (0.58) GRM5NPC1RAB9ALMNAHPGD
SCHEMBL14266553 0.84 BRAF (0.55) GRM5NPC1RAB9ALMNAHPGD
SCHEMBL3986272 0.82 NR3C2 (0.45) GRM5BRAFCA1CA2CA7
SCHEMBL3994618 0.82 RAF1 (0.54) GRM5BRAFKDM4EHDAC2HDAC8
SCHEMBL5118325 0.81 RAB9A (0.51) GRM5NPC1RAB9ALMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061761-A1 PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY Millennium Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
WO-2008030448-A1 PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MAP4K5, MAP3K5, MAP4K2 GRM5 830/4885NPC1 3081/4885RAB9A 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.